TIMI UA/NSTEMI Risk Score Calculator for Acute Coronary Syndrome

About

The TIMI (Thrombolysis In Myocardial Infarction) risk score for unstable angina and non-ST-elevation myocardial infarction was developed by Antman et al. and published in JAMA in 2000 based on data from two landmark randomized controlled trials: TIMI 11B (which compared enoxaparin to unfractionated heparin) and ESSENCE (which also evaluated enoxaparin versus unfractionated heparin in unstable angina and NSTEMI). The derivation cohort included 1,958 patients with UA/NSTEMI from TIMI 11B, and the score was validated in 1,952 patients from the ESSENCE trial. The score identifies seven independent predictors of adverse outcomes at 14 days, including age ≥65 years, at least three coronary artery disease risk factors, known coronary artery disease (stenosis ≥50%), aspirin use within the past seven days, severe angina (at least two anginal episodes within 24 hours), ST-segment deviation ≥0.5 mm on presenting ECG, and elevated serum cardiac biomarkers (troponin or creatine kinase MB fraction). Each variable carries equal weight at 1 point, yielding a total score ranging from 0 to 7. The 14-day composite endpoint of all-cause mortality, new or recurrent myocardial infarction, or severe recurrent ischemia requiring urgent revascularization ranges from 4.7% for a score of 0-2 to 29.3% for a score of 5-7. The score has been externally validated in multiple populations including community-based cohorts, registries, and clinical trial datasets, with consistent prognostic performance. Its evidence level is Grade B, supported by the original derivation and validation trials as well as subsequent confirmatory studies.

Formula

Age ≥65 (1) + ≥3 CAD Risk Factors (1) + Known CAD (1) + Aspirin in Past 7 Days (1) + Severe Angina (1) + ST Deviation ≥0.5mm (1) + Elevated Cardiac Markers (1)

The TIMI UA/NSTEMI risk score assigns 1 point for each of seven independent clinical variables present at the time of initial evaluation, yielding a total score from 0 to 7. Age ≥65 years contributes 1 point, reflecting the increased vulnerability to adverse outcomes associated with advanced age. The presence of at least three traditional CAD risk factors (family history of premature CAD, hypertension, diabetes, hyperlipidemia, smoking, or obesity) adds 1 point. Known coronary artery disease — defined as prior angiographic stenosis ≥50%, prior myocardial infarction, prior percutaneous coronary intervention, or prior coronary artery bypass grafting — adds 1 point. Aspirin use within the seven days preceding presentation contributes 1 point, as this identifies patients with more advanced or unstable atherosclerotic disease. Severe angina, defined as two or more anginal episodes within the 24 hours preceding presentation, adds 1 point and reflects ongoing myocardial ischemia. ST-segment deviation of 0.5 mm or more on the presenting ECG (either ST depression or transient ST elevation) contributes 1 point, identifying patients with electrocardiographic evidence of active ischemia. Elevated serum cardiac biomarkers (troponin I or T, or creatine kinase MB fraction above the upper limit of normal) contribute 1 point, reflecting myocardial necrosis. The total score stratifies patients into three risk categories: low risk (score 0-2, 14-day composite event rate 4.7%), moderate risk (score 3-4, event rate 12.5%), and high risk (score 5-7, event rate 29.3%). Each additional point increases the risk of adverse outcomes by approximately 4-5%, demonstrating a clear risk gradient that guides clinical decision-making regarding the intensity of antithrombotic therapy and the timing of invasive coronary angiography.

Score Interpretation

The TIMI UA/NSTEMI risk score is a cornerstone of early risk stratification in acute coronary syndrome management, endorsed by the AHA/ACC guideline for the management of patients with acute coronary syndromes and the ESC guidelines for NSTEMI. Its clinical utility lies in its simplicity — seven binary variables that can be assessed within minutes of presentation using history, ECG, and initial cardiac biomarker results — and its ability to provide a clear risk gradient that informs therapeutic decision-making. For low-risk patients (score 0-2), the score supports a conservative initial strategy with medical management, serial biomarker monitoring, and non-invasive stress testing before discharge. For moderate-risk patients (score 3-4), the score supports admission with antithrombotic therapy (anticoagulation plus dual antiplatelet therapy) and early invasive coronary angiography within 24-48 hours. For high-risk patients (score 5-7), the score supports an urgent invasive strategy (angiography within 24 hours), intensive antithrombotic therapy with a P2Y12 inhibitor (ticagrelor or prasugrel) in addition to aspirin and anticoagulation, and close monitoring in a cardiac care unit. The score has also been shown to predict long-term outcomes beyond 14 days, including 1-year mortality and recurrent ischemic events, thereby providing prognostic information relevant to both acute and chronic management planning. Despite the emergence of newer risk scores and biomarkers, TIMI UA/NSTEMI remains widely used due to its simplicity, rapid calculation, and robust validation across diverse patient populations and clinical settings.

Reference Ranges